Check out our latest review👏! We dive deep into how cDC1s orchestrate anti-tumor immunity through cross-presentation, immune networking, and spatial organization.

Nina Bhardwaj, MD, PhD, is on the Scientific Organizing Committee. @EdgarEGK is a speaker. Kelsey Monson, PhD, MS, is presenting a poster. @BhardwajLab @IcahnMountSinai

Courau et al. profiled immune landscapes of 15 common mouse tumor models alongside human datasets. Most murine TIMEs resembled a minority subset of macrophage-rich, poorly infiltrated human tumors. Cross-species analysis showed species-specific biases in chemokine networks (including reduced CCR2/CCR5 and altered CXCL13 in mice) and altered T and myeloid cell frequencies, while conserved cell-type specific gene expression programs emerged as discriminatory. An IFN-responsive myeloid–CD8 T cell cytotoxicity module was conserved across tumor types, and predicted clinical outcome in humans. bit.ly/3RK2oi1 @alexis_combes @CourauTristan @MaxKrummel @GabiFragiadakis

Presented at #ASCO26: Among patients with previously treated metastatic pancreatic ductal adenocarcinoma, the RAS(ON) inhibitor daraxonrasib led to significantly longer overall survival and progression-free survival than chemotherapy. Full phase 3 RASolute 302 trial results: nej.md/4nWaxvM @ASCO

Huge congratulations to @michelle_a_tran on graduating!🎓 The Bhardwaj lab team loved celebrating your incredible hard work and achievements over dinner. We are so proud of you and can't wait to see what you do next!✨ Cheers to the next chapter!🥂 #LabFamily #Graduation

Immune-remodeling mRNAs expressing IRF8 or NIK generate durable antitumor immunity in multiple cancer models go.nature.com/42td2fh

Trading pipettes for axes! Lab bonding last week was a 10/10 vibe. Looking at the lineup, who do you think lowkey had the best aim?🎯

Huge congratulations to Michelle on officially finishing her MD-PhD. It’s been an incredible journey watching her balance the bench and the clinic with such dedication. We couldn’t be prouder of everything she’s accomplished. Cheers to Dr. Michelle!🥂 ##MDPhD #Graduation

Reprogramming T cell-myeloid crosstalk overcomes immune resistance in colorectal cancer: Cell Reports Medicine cell.com/cell-reports-medici… @BhardwajLab @IcahnMountSinai

Huge congratulations to Michelle! So proud to see you graduate!

Enjoy this little cartoon summarizing Guillaume's latest work in Cell Reports Medicine! cell.com/cell-reports-medici…

mRNA vaccine immunity is enhanced by hepatocyte detargeting and not dependent on dendritic cell expression go.nature.com/4eSjV0N

We are thrilled to share our latest work uncovering how the SPP1 macrophage-driven inflammatory axis fuels immune evasion in bladder cancer. Fantastic job by Michelle and all our collaborators! 👏

A year after NIH funding cuts, 27% of researchers report their funding hasn’t been restored. This is not just budgets; it is the future of science, and the impact is already being felt, as @cassiemcgrath_ reports in @HealthcareBrew. As PICI CEO @DrKarenKnudsen shared with Healthcare Brew, these funding cuts have a large impact on researchers and patients, and stall bold innovative science. PICI is working to keep progress moving by backing high-risk, high-reward science and accelerating collaboration to turn all cancers into curable diseases. Read Cassie’s full piece here: healthcare-brew.com/stories/…

Nie, Liu, Song, and Yao et al. developed a spleen delivery platform of mRNA-loaded lipid nanoparticles (LNPs) covalently bound to erythrocytes (mRNA-LNP-Ery), which naturally target splenic CD11b myeloid cells. Unlike conventional LNPs, mRNA-LNP-Ery entered cells via phagocytosis, avoiding lysosomal degradation and efficiently delivering mRNA. CAR myeloid cells (HER2 or CD19) adopted a proinflammatory antigen-presenting phenotype, migrated to tumors, and stimulated T and NK cell influx, potent antitumor activity, and systemic immunity, which was spleen-dependent. Repeated doses of mRNA-LNP-Ery resulted in superior efficacy at 1/10 the dose of LNPs. bit.ly/4dKws67

Nature research paper: mRNA vaccines engage unconventional pathways in CD8 T cell priming go.nature.com/3QbmxwB

⏳ 2 days left! Abstract submission for #DC2026 closes April 17 🌍 Join the global DC community in San Diego Submit your work now — don’t miss it! dc2026sandiego.com @MaxKrummel @ZunigaLab 🔁

Dr. Nina Bhardwaj will be at #AACR26! Looking forward to connecting, engaging, and discussing the latest in cancer immunology @AACR